Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Ousseny Zerbo and Allison Naleway.
Ousseny Zerbo
Connection Strength
2.344
Allison Naleway
  1. Effectiveness of Recombinant Zoster Vaccine Against Herpes Zoster in a Real-World Setting. Ann Intern Med. 2024 Jan 09.
    View in: PubMed
    Score: 0.240
  2. Influenza Vaccination Among Pregnant People Before and During the Coronavirus Disease 2019 (COVID-19) Pandemic. Obstet Gynecol. 2023 09 01; 142(3):636-639.
    View in: PubMed
    Score: 0.233
  3. Estimation of COVID-19 mRNA Vaccine Effectiveness Against Medically Attended COVID-19 in Pregnancy During Periods of Delta and Omicron Variant Predominance in the United States. JAMA Netw Open. 2022 09 01; 5(9):e2233273.
    View in: PubMed
    Score: 0.218
  4. Vaccine Safety Datalink infrastructure enhancements for evaluating the safety of maternal vaccination. Ther Adv Drug Saf. 2021; 12:20420986211021233.
    View in: PubMed
    Score: 0.201
  5. Obstetric Complications and Birth Outcomes After Antenatal Coronavirus Disease 2019 (COVID-19) Vaccination. Obstet Gynecol. 2024 Jun 01; 143(6):794-802.
    View in: PubMed
    Score: 0.061
  6. Medically Attended Acute Adverse Events in Pregnant People After Coronavirus Disease 2019 (COVID-19) Booster Vaccination. Obstet Gynecol. 2023 Jul 01; 142(1):125-129.
    View in: PubMed
    Score: 0.057
  7. Effectiveness of BNT162b2 COVID-19 Vaccination in Children and Adolescents. Pediatrics. 2023 05 01; 151(5).
    View in: PubMed
    Score: 0.057
  8. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022. MMWR Morb Mortal Wkly Rep. 2023 Mar 17; 71(53):1637-1646.
    View in: PubMed
    Score: 0.057
  9. Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods. JAMA Netw Open. 2023 03 01; 6(3):e232598.
    View in: PubMed
    Score: 0.057
  10. Vaccine effectiveness against influenza-associated urgent care, emergency department, and hospital encounters during the 2021-2022 season, VISION Network. J Infect Dis. 2023 Jan 23.
    View in: PubMed
    Score: 0.056
  11. Relationships between social vulnerability and COVID-19 vaccination coverage and vaccine effectiveness. Clin Infect Dis. 2023 Jan 06.
    View in: PubMed
    Score: 0.056
  12. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults - VISION Network, Nine States, September-November 2022. MMWR Morb Mortal Wkly Rep. 2022 Dec 30; 71(5152):1616-1624.
    View in: PubMed
    Score: 0.056
  13. Protection of 2 and 3 mRNA Vaccine Doses Against Severe Outcomes Among Adults Hospitalized with COVID-19 - VISION Network, August 2021 - March 2022. J Infect Dis. 2022 Nov 23.
    View in: PubMed
    Score: 0.055
  14. Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance - VISION Network, 10 States, December 2021-August 2022. MMWR Morb Mortal Wkly Rep. 2022 Oct 21; 71(42):1335-1342.
    View in: PubMed
    Score: 0.055
  15. Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study. BMJ. 2022 10 03; 379:e072141.
    View in: PubMed
    Score: 0.055
  16. Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated - VISION Network, 10 States, December 2021-June 2022. MMWR Morb Mortal Wkly Rep. 2022 Jul 22; 71(29):931-939.
    View in: PubMed
    Score: 0.054
  17. Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination. Vaccine. 2022 08 19; 40(35):5153-5159.
    View in: PubMed
    Score: 0.054
  18. Evaluation of Acute Adverse Events after Covid-19 Vaccination during Pregnancy. N Engl J Med. 2022 07 14; 387(2):187-189.
    View in: PubMed
    Score: 0.054
  19. Safety of COVID-19 Vaccination in US Children Ages 5-11 Years. Pediatrics. 2022 May 18.
    View in: PubMed
    Score: 0.054
  20. Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults - VISION Network, 10 States, December 2021-March 2022. MMWR Morb Mortal Wkly Rep. 2022 Apr 01; 71(13):495-502.
    View in: PubMed
    Score: 0.053
  21. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Mar 04; 71(9):352-358.
    View in: PubMed
    Score: 0.053
  22. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Feb 18; 71(7):255-263.
    View in: PubMed
    Score: 0.053
  23. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Jan 21; 71(4):139-145.
    View in: PubMed
    Score: 0.052
  24. Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults-Nine States, January-September 2021. Am J Transplant. 2022 01; 22(1):306-314.
    View in: PubMed
    Score: 0.052
  25. Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1539-1544.
    View in: PubMed
    Score: 0.052
  26. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1553-1559.
    View in: PubMed
    Score: 0.052
  27. Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings. N Engl J Med. 2021 Sep 08.
    View in: PubMed
    Score: 0.051
  28. Surveillance for Adverse Events After COVID-19 mRNA Vaccination. JAMA. 2021 Sep 03.
    View in: PubMed
    Score: 0.051
  29. COVID-19 Vaccination Coverage Among Insured Persons Aged =16 Years, by Race/Ethnicity and Other Selected Characteristics - Eight Integrated Health Care Organizations, United States, December 14, 2020-May 15, 2021. MMWR Morb Mortal Wkly Rep. 2021 Jul 16; 70(28):985-990.
    View in: PubMed
    Score: 0.050
  30. COVID-19 Vaccination Coverage Among Pregnant Women During Pregnancy - Eight Integrated Health Care Organizations, United States, December 14, 2020-May 8, 2021. MMWR Morb Mortal Wkly Rep. 2021 Jun 18; 70(24):895-899.
    View in: PubMed
    Score: 0.050
  31. Trivalent inactivated influenza vaccine (IIV3) during pregnancy and six-month infant development. Vaccine. 2020 02 28; 38(10):2326-2332.
    View in: PubMed
    Score: 0.046

© 2024 Kaiser Permanente